Vertex Pharma (VRTX) Begins Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as Triple Combination Regimen for People with Cystic Fibrosis
Tweet Send to a Friend
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that it is initiating two Phase 3 studies of VX-445, tezacaftor and ivacaftor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
